Compound: pyridostigmine
SMILES: O=C(Oc1c[n+](ccc1)C)N(C)C
InChIKey: RVOLLAQWKVFTGE-UHFFFAOYSA-N
Synonyms: pyridostigmine, 155-97-5, Pyridostigminum, Pyridostigmine cation, (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate, Pyridostigmine ion, 3-((Dimethylcarbamoyl)oxy)-1-methylpyridin-1-ium, 19QM69HH21, Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-, DTXSID20165786, 3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium, Pyridinium, 3-hydroxy-1-methyl-, bromide, dimethylcarbamate (ester), RefChem:55945, DTXCID3088277, Pyridostigmine Bromine, CHEMBL812, BRN 1428269, 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium, UNII-19QM69HH21, Spectrum_001603, 1-methyl-3-pyridiniumyl dimethylcarbamate, Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester), Spectrum2_000861, Spectrum3_001909, Spectrum5_001046, Lopac-P-9797, SCHEMBL1317, CHEMBL1115, Lopac0_001035, BSPBio_003478, KBioSS_002083, 5-21-02-00078 (Beilstein Handbook Reference), AQ-776/42801589, BIDD:GT0384, DivK1c_000207, PYRIDOSTIGMINE [VANDF], SPBio_000901, CHEBI:8665, GTPL8994, orb1298763, PYRIDOSTIGMINE [WHO-DD], SCHEMBL29356532, KBio1_000207, KBio2_002083, KBio2_004651, KBio2_007219, KBio3_002982, NINDS_000207, C9H13N2O2+, ALBB-038602, BDBM50313079, MFCD00242986, SBB089804, AKOS025310658, CCG-205113, DB00545, IDI1_000207, NCGC00015862-01, NCGC00015862-02, NCGC00015862-03, NCGC00015862-04, NCGC00015862-05, NCGC00015862-06, NCGC00015862-16, NCGC00023921-03, NCI60_028530, SBI-0051006.P002, NS00007951, C07410, H58317, AB00053819-13, AB00053819_14, AB00053819_15, N,N-dimethyl(1-methyl(3-pyridyloxy))carboxamide, Q419472, 3-Dimethylcarbamoyloxy-1-methyl-pyridinium; bromide, 3-((DIMETHYLCARBAMOYL)OXY)-1-METHYLPYRIDINIUM, BRD-K69688083-004-22-3, BRD-K69688083-004-23-1
Theoretical properties:
molecular_formula: C9H13N2O2+
molecular_weight: 181.21 g/mol
exact_mass: 181.097702662 g/mol
formal_charge: 1
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 2
heavy_atom_count: 13
topological_polar_surface_area: 33.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 152-154
Descriptions:
pubchem: Pyridostigmine is a pyridinium ion.
chembl: PYRIDOSTIGMINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Pyridostigmine is a medication used to treat myasthenia gravis and underactive bladder. It is also used together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type. It is also used off-label to treat some forms of Postural orthostatic tachycardia syndrome. It is typically given by mouth but can also be used by injection. When administrated orally the effects generally begin within 15–30 minutes and last up to 4 hours.
Common side effects include nausea, diarrhea, frequent urination, sweating, and abdominal pain. More severe side effects include low blood pressure, weakness, and allergic reactions. It is unclear if use in pregnancy is safe for the fetus. Pyridostigmine is an acetylcholinesterase inhibitor in the cholinergic family of medications. It works by blocking the action of acetylcholinesterase and therefore increases the levels of acetylcholine.
Pyridostigmine was patented in 1945 and came into medical use in 1955. It is on the World Health Organization's List of Essential Medicines. Pyridostigmine is available as a generic medication.